Article
HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration.
PLoS biology - 1 Nov 2013
Mielcarek Michal, Landles Christian, Weiss Andreas, Bradaia Amyaouch, Seredenina Tamara, Inuabasi Linda, Osborne Georgina F, Wadel Kristian, Touller Chrystelle, Butler Rachel, Robertson Janette, Franklin Sophie A, Smith Donna L, Park Larry, Marks Paul A, Wanker Erich E, Olson Eric N, Luthi-Carter Ruth, van der Putten Herman, Beaumont Vahri, Bates Gillian P
Abstract excerpt
Histone deacetylase (HDAC) 4 is a transcriptional repressor that contains a glutamine-rich domain. We hypothesised that it may be involved in the molecular pathogenesis of Huntington's disease (HD), a protein-folding neurodegenerative disorder caused by an aggregation-prone polyglutamine expansion in the huntingtin protein. We found that HDAC4 associates with huntingtin in a polyglutamine-length-dependent manner...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
